Catalyst Clinical Research Wins the Excellence in Clinical Trial Management Award

Fierce CRO Awards acknowledge the company's focus to deliver for our customers 

WILMINGTON, N.C., June 18, 2025 /PRNewswire/ -- Catalyst Clinical Research today proudly announces it has won the Excellence in Clinical Trial Management category in the Fierce CRO Awards by Fierce Biotech.

This prestigious recognition highlights Catalyst's dedication to delivering high-quality, flexible clinical trial solutions to meet the evolving needs of its sponsors. In one notable study, Catalyst's strategic recommendations for study design changes laid the foundation for a successful outcome. The trial not only exceeded enrollment goals but also achieved a promising endpoint analysis, enabling the sponsor to pursue a Breakthrough Therapy Designation and potential registrational submission.

The Fierce CRO Awards celebrate outstanding achievements and innovations by contract research organizations (CROs) that demonstrate excellence in performance, innovation, and leadership in clinical research. Catalyst's win underscores its critical role in advancing life sciences research and improving patient outcomes. 

"Our teams are committed to supporting our clients in bringing new therapies to patients," said Nik Morton, President and CEO of Catalyst Clinical Research. "Winning this award is a tremendous honor and a testament to the passion, expertise, and dedication of our entire organization."

The Fierce CRO Awards winners were judged on: Innovation and Impact, Measurable Outcomes, Sustainability and Scalability and Ethical and Regulatory Adherence.

Catalyst is honored to be recognized among the industry's best and remains steadfast in its mission to deliver excellence in every trial. 

About Catalyst Clinical Research
Catalyst Clinical Research, a contract research organization (CRO), provides highly customizable solutions to the global biopharmaceutical and biotechnology industries through two established, branded solutions: Catalyst Oncology and Catalyst Flex. The company provides full-service oncology CRO offerings with Catalyst Oncology and multi-therapeutic customer- or Catalyst-managed functional services through Catalyst Flex. With more than 1,000 staff and several offices in the United States, Europe, and the Asia-Pacific region, Catalyst's flexible service model is built from more than a decade of listening to customers, devising customer-centric solutions, and helping customers advance their clinical studies by leveraging expert teams and innovative technologies. Visit Catalyst online at CatalystCR.com or follow us on LinkedIn.   

Catalyst is a portfolio company of QHP Capital, a healthcare and life sciences investment firm.   

About Fierce Biotech
Fierce Biotech is the biotech industry's daily monitor, providing the latest news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 300,000 top biotech professionals rely on Fierce Biotech for an insider briefing on the day's top stories. Signup is free here. 

Media Contact:
Elizabeth Humphrey
[email protected]
+1 (984) 459-2090

SOURCE Catalyst Clinical Research